迈瑞医疗66.52亿元收购惠泰医疗21%股份

证券时报01-29

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　迈瑞医疗（300760）1月28日晚公告，公司拟通过全资子公司深迈控以协议转让方式收购惠泰医疗（688617）21.12%股份，转让金额合计约66.52亿元。惠泰医疗实际控制人成正辉承诺，将不可撤销地放弃所持惠泰医疗10%股份所享有的表决权。　　同时，深迈控拟受让晨壹红启持有的珠海彤升全部0.12%的普通合伙权益（...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2407078071?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-01-29 06:59","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2407078071","market":"fut","top_or_hot":-1,"title":"迈瑞医疗66.52亿元收购惠泰医疗21%股份","media":"证券时报","content":"<div>\n<p>炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 　　迈瑞医疗（300760）1月28日晚公告，公司拟通过全资子公司深迈控以协议转让方式收购惠泰医疗（688617）21.12%股份，转让金额合计约66.52亿元。惠泰医疗实际控制人成正辉承诺，将不可撤销地放弃所持惠泰医疗10%股份所享有的表决权。\n　　同时，深迈控拟受让晨壹红启持有的珠海彤升全部0.12%的普通合伙权益（...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/s/2024-01-29/doc-inafctks8709418.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>迈瑞医疗66.52亿元收购惠泰医疗21%股份</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n迈瑞医疗66.52亿元收购惠泰医疗21%股份\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-29 06:59 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/s/2024-01-29/doc-inafctks8709418.shtml><strong>证券时报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 　　迈瑞医疗（300760）1月28日晚公告，公司拟通过全资子公司深迈控以协议转让方式收购惠泰医疗（688617）21.12%股份，转让金额合计约66.52亿元。惠泰医疗实际控制人成正辉承诺，将不可撤销地放弃所持惠泰医疗10%股份所享有的表决权。\n　　同时，深迈控拟受让晨壹红启持有的珠海彤升全部0.12%的普通合伙权益（...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/s/2024-01-29/doc-inafctks8709418.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1064131003.USD","symbol_name":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","start_time":0,"source_url":"https://finance.sina.com.cn/stock/s/2024-01-29/doc-inafctks8709418.shtml","article_id":"2407078071","we_media_id":null,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/s/2024-01-29/doc-inafctks8709418.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2407078071","pubTimestamp":1706482740,"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"　　迈瑞医疗1月28日晚公告，公司拟通过全资子公司深迈控以协议转让方式收购惠泰医疗21.12%股份，转让金额合计约66.52亿元。惠泰医疗实际控制人成正辉承诺，将不可撤销地放弃所持惠泰医疗10%股份所享有的表决权。　　同时，深迈控拟受让晨壹红启持有的珠海彤升全部0.12%的普通合伙权益，珠海彤升目前持有惠泰医疗3.49%的股份。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300760":"迈瑞医疗","688617":"惠泰医疗","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","IE0008368742.USD":"首域中国增长基金I Acc","LU2153592121.USD":"Aberdeen Standard SICAV I - Emerging Markets Sustainable Development Equity A Acc USD","LU1720050803.USD":"安联全方位中国股票基金","SGXZ81163826.USD":"UNITED CHINA A-SHARES INNOVATION \"A\" (USD) ACC","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2153591404.USD":"Aberdeen Standard SICAV I - Asian Sustainable Development Equity A Acc USD","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0084288322.USD":"Natixis Asia Equity RD USD","LU2348774022.SGD":"Aberdeen Standard SICAV I - Emerging Markets Sustainable Development Equity A Acc SGD-H","BK0251":"专用设备","LU0823426308.USD":"法巴中国股票基金","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","SGXZ49509284.SGD":"United China A Shares Innovation A Acc SGD","LU0823426480.USD":"法巴中国股票经典Dis","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU0359201612.USD":"贝莱德中国基金A2","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2348773727.SGD":"Aberdeen Standard SICAV I - Asian Sustainable Development Equity A Acc SGD-H","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H"},"translate_title":"Mindray Medical acquired 21% shares of Huitai Medical for 6.652 billion yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300760":1,"688617":1},"content_text":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 　　迈瑞医疗（300760）1月28日晚公告，公司拟通过全资子公司深迈控以协议转让方式收购惠泰医疗（688617）21.12%股份，转让金额合计约66.52亿元。惠泰医疗实际控制人成正辉承诺，将不可撤销地放弃所持惠泰医疗10%股份所享有的表决权。\n　　同时，深迈控拟受让晨壹红启持有的珠海彤升全部0.12%的普通合伙权益（迈瑞医疗持有珠海彤升99.88%的有限合伙权益），珠海彤升目前持有惠泰医疗3.49%的股份。\n　　本次交易完成后，深迈控及其一致行动人珠海彤升合计持有惠泰医疗24.61%股份，惠泰医疗控股股东将变更为深迈控，实际控制人将变更为李西廷和徐航。\n　　1月28日晚，惠泰医疗也同步发布相关公告。惠泰医疗的主营业务为电生理、冠脉通路及外周血管介入等产品的研发生产，为我国电生理领域国产龙头企业及心血管领域国产领先企业，具备深厚的技术储备与丰富的产品矩阵。\n　　惠泰医疗1月25日披露2023年业绩预告，公司预计2023年净利润5.1亿元至5.65亿元，同比增加42.45%到57.81%；预计实现扣非净利润4.45亿元至5.05亿元，同比增加38.38%到56.78%。\n　　谈及2023年业绩同比增长的主要原因，惠泰医疗表示，公司持续开展各类市场营销活动，快速拓展医院覆盖率和渗透率，不断扩大品牌知名度和影响力，积极拓展海外市场，2023年各产品线较上年同期均有不同程度增长。公司通过研发持续优化、升级产品，改进工艺，不断提升自动化制造水平，提升产品竞争力和盈利能力。\n　　惠泰医疗1月28日晚公告，本次交易完成后，成正辉将继续担任公司副董事长及总经理职务，持续发挥其在公司研发、生产、营销、运营等多方面的重要作用。深迈控及其控股股东迈瑞医疗目前暂无在未来改变公司主营业务或者对公司主营业务作出重大调整的计划，将保持公司管理层及核心员工团队稳定，并在保持公司现有业务稳定发展同时，结合自身资源及管理经验，推进公司长期健康发展。\n　　迈瑞医疗看好电生理等心血管产品的市场发展趋势，不断构建和丰富耗材型业务布局是公司重要发展战略方向之一，为此迈瑞医疗积极寻找全球优秀标的进行并购整合，期望实现内外协同发展。\n　　近年来，迈瑞医疗格外重视外延式并购为公司发展带来的驱动效应。2021年，公司就收购了全球知名的IVD原材料领域公司海肽生物（HyTest），实现了在IVD原材料领域核心技术的自主可控。2023年，迈瑞医疗再次完成对德国DiaSys控股收购，成功构建起体外诊断产品全球供应链平台，为实现IVD业务的全面国际化奠定基础。\n　　据迈瑞医疗最新公告，通过本次交易，公司将以此进入心血管领域相关赛道，并将利用在医疗器械领域的积累和人才储备，助力惠泰医疗提升研发能力、优化产品性能。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：杨红艳","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2407078071"}